Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Malignant Lymphoma

  Free Subscription


Articles published in Eur J Haematol

Retrieve available abstracts of 74 articles:
HTML format



Single Articles


    March 2024
  1. GARCIA-POUTON N, Ortiz-Maldonado V, Peyrony O, Chumbita M, et al
    Infection epidemiology in relation to different therapy phases in patients with haematological malignancies receiving CAR T-cell therapy.
    Eur J Haematol. 2024;112:371-378.
    PubMed     Abstract available


    February 2024
  2. HEGER JM, d'Hargues Y, Kleinert F, Mattlener J, et al
    Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR.
    Eur J Haematol. 2024 Feb 18. doi: 10.1111/ejh.14191.
    PubMed     Abstract available


  3. MASSOUD R, Naim H, Klyuchnikov E, Janson D, et al
    Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas.
    Eur J Haematol. 2024;112:276-285.
    PubMed     Abstract available


  4. HO M, Zanwar S, Paludo J
    Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
    Eur J Haematol. 2024;112:197-210.
    PubMed     Abstract available


    January 2024
  5. YAMAUCHI N, Maruyama D
    Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma.
    Eur J Haematol. 2024 Jan 3. doi: 10.1111/ejh.14166.
    PubMed     Abstract available


  6. ZEREMSKI V, Adolph L, Beer S, Berisha M, et al
    Relevance of different prognostic scores in primary CNS lymphoma in the era of intensified treatment regimens: A retrospective, multicenter analysis of 174 patients.
    Eur J Haematol. 2024 Jan 2. doi: 10.1111/ejh.14159.
    PubMed     Abstract available


  7. GUPTA S, Kohorst M, Alkhateeb HB
    Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2024;112:51-63.
    PubMed     Abstract available


    December 2023
  8. LOPEZ M, Kainthla R, Lazarte S, Chen W, et al
    Outcomes in Kaposi's sarcoma-associated herpesvirus -associated primary effusion lymphoma and multicentric Castleman's disease in patients with human immunodeficiency virus (HIV) in a safety-net hospital system.
    Eur J Haematol. 2023 Dec 28. doi: 10.1111/ejh.14163.
    PubMed     Abstract available


  9. RAMDANY H, Lofaro T, Deplano S
    The Haemato-Oncology Frailty (HOF) score to assess frailty in lymphoma.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14152.
    PubMed     Abstract available


  10. MORI T, Osumi T, Kada A, Ohki K, et al
    Rituximab with standard LMB chemotherapy in pediatric high-risk mature B-cell non-Hodgkin lymphoma: A report from the JPLSG B-NHL14 trial.
    Eur J Haematol. 2023 Dec 19. doi: 10.1111/ejh.14148.
    PubMed     Abstract available


    October 2023
  11. BREINHOLT MF, Schejbel L, Gang AO, Nielsen TH, et al
    Next generation sequencing in routine diagnostics of mature non-Hodgkin's B-cell lymphomas.
    Eur J Haematol. 2023;111:583-591.
    PubMed     Abstract available


    September 2023
  12. AGRAWAL V, Murphy L, Pourhassan H, Pullarkat V, et al
    Optimizing CAR-T cell therapy in adults with B-cell acute lymphoblastic leukemia.
    Eur J Haematol. 2023 Sep 29. doi: 10.1111/ejh.14109.
    PubMed     Abstract available


  13. ZHU H, Zhuang Z, Wang W, Zhao D, et al
    Three cases of late-onset post CAR-T therapy isolated CNS relapse in R/R large B-cell lymphoma.
    Eur J Haematol. 2023 Sep 18. doi: 10.1111/ejh.14078.
    PubMed     Abstract available


  14. CHATTERJEE G, Dhende P, Raj S, Shetty V, et al
    15-color highly sensitive flow cytometry assay for post anti-CD19 targeted therapy (anti-CD19-CAR-T and blinatumomab) measurable residual disease assessment in B-lymphoblastic leukemia/lymphoma: Real-world applicability and challenges.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14102.
    PubMed     Abstract available


  15. CAI F, Zhang J, Gao H, Shen H, et al
    Tumor microenvironment and CAR-T cell immunotherapy in B-cell lymphoma.
    Eur J Haematol. 2023 Sep 14. doi: 10.1111/ejh.14103.
    PubMed     Abstract available


    August 2023
  16. VAN HEEK L, Weindler J, Gorniak C, Kaul H, et al
    Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early-stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial.
    Eur J Haematol. 2023 Aug 29. doi: 10.1111/ejh.14093.
    PubMed     Abstract available


  17. KURTE MS, Siefen AC, Jakobs F, von Tresckow B, et al
    Cost-effectiveness analysis of transplant-ineligible relapsed or refractory diffuse large B-cell lymphoma treatment options-Experience of the efficiency frontier approach.
    Eur J Haematol. 2023 Aug 29. doi: 10.1111/ejh.14095.
    PubMed     Abstract available


  18. AMITAI I, Roos K, Rashedi I, Jiang Y, et al
    PD-L1 expression predicts efficacy in the phase II SPiReL trial with MVP-S, pembrolizumab, and low-dose CPA in R/R DLBCL.
    Eur J Haematol. 2023;111:191-200.
    PubMed     Abstract available


    July 2023
  19. MATTSSON A, Sylvan SE, Axelsson P, Ellin F, et al
    Idelalisib (PI3Kdelta inhibitor) therapy for patients with relapsed/refractory chronic lymphocytic leukemia: A Swedish nation-wide real-world report on consecutively identified patients.
    Eur J Haematol. 2023 Jul 27. doi: 10.1111/ejh.14065.
    PubMed     Abstract available


    June 2023
  20. QIN Y, He X, Chen X, Xie Z, et al
    Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients.
    Eur J Haematol. 2023 Jun 9. doi: 10.1111/ejh.14013.
    PubMed     Abstract available


    May 2023
  21. CENCINI E, Rocco M, Ghio F, Simonetti F, et al
    Long-term efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma achieving a complete response with pixantrone.
    Eur J Haematol. 2023 May 10. doi: 10.1111/ejh.13989.
    PubMed     Abstract available


    April 2023
  22. METZNER B, Muller TH, Casper J, Kimmich C, et al
    Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
    Eur J Haematol. 2023 Apr 24. doi: 10.1111/ejh.13985.
    PubMed     Abstract available


    March 2023
  23. ONG SY, Chen Y, Yun MTS, Ho Yew Leng A, et al
    Current perspectives on resistance to CAR T-cell therapy and strategies to improve efficacy in B-cell lymphoma.
    Eur J Haematol. 2023 Mar 29. doi: 10.1111/ejh.13964.
    PubMed     Abstract available


  24. BUEGE MJ, Drill E, Horwitz SM, LeVoir A, et al
    Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
    Eur J Haematol. 2023 Mar 27. doi: 10.1111/ejh.13971.
    PubMed     Abstract available


  25. KATZ OB, Perry C, Greenzaid SG, Ofir DY, et al
    Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study.
    Eur J Haematol. 2023 Mar 25. doi: 10.1111/ejh.13968.
    PubMed     Abstract available


  26. MITROVIC Z, Dujmovic D, Jaksic O, Kinda SB, et al
    Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: a real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
    Eur J Haematol. 2023 Mar 20. doi: 10.1111/ejh.13957.
    PubMed     Abstract available


  27. SHENG Z, Wang L
    Superiority of ibrutinib plus bendamustine and rituximab in newly diagnosed patients with mantle-cell lymphoma ineligible for intensive therapy: a network meta-analysis.
    Eur J Haematol. 2023 Mar 14. doi: 10.1111/ejh.13953.
    PubMed     Abstract available


    February 2023
  28. GAO H, Lin N, Gu Z, Zhao S, et al
    Up-front Autologous Hematopoietic Stem Cell Transplantation After First Complete Remission Improved Prognosis of Advanced Extra nodal NKT Cell Lymphoma: A Multicenter Real-World Study in China.
    Eur J Haematol. 2023 Feb 24. doi: 10.1111/ejh.13950.
    PubMed     Abstract available


  29. WANG Y, Li J, Xue TL, Tian S, et al
    Clinical, biological and outcome features of P2RY8-CRLF2 and CRLF2 over-expression in pediatric B-cell precursor acute lymphoblastic leukemia according to the CCLG-ALL 2008 and 2018 protocol.
    Eur J Haematol. 2023 Feb 22. doi: 10.1111/ejh.13948.
    PubMed     Abstract available


  30. YUE X, Hallett D, Liu Y, Basa E, et al
    Outcomes of coronavirus disease 2019 (COVID-19) and risk factors associated with severe COVID-19 in patients with mature B-cell non-Hodgkin lymphomas: A US electronic health record cohort study.
    Eur J Haematol. 2023;110:177-187.
    PubMed     Abstract available


  31. SHARGIAN L, Amit O, Bernstine H, Gurion R, et al
    The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter study.
    Eur J Haematol. 2023;110:149-156.
    PubMed     Abstract available


    January 2023
  32. TEY A, Schwarer J, Raffa R, Shi E, et al
    High risk of infection in 'real-world' patients receiving ibrutinib, idelalisib or venetoclax for mature B-cell leukaemia/lymphoma.
    Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13928.
    PubMed     Abstract available


  33. ELLIOTT EK, Hensen R, Haupt LM, Griffiths LR, et al
    Global reported impacts of COVID-19 on lymphoma patients and the emerging clinical management approaches in response to the ongoing pandemic.
    Eur J Haematol. 2023 Jan 19. doi: 10.1111/ejh.13926.
    PubMed     Abstract available


    December 2022
  34. NGUYEN J, Wellard C, Chung E, Cheah CY, et al
    Clinical characteristics of Australian treatment-naive patients with classical Hodgkin Lymphoma from the Lymphoma and Related Diseases Registry.
    Eur J Haematol. 2022 Dec 20. doi: 10.1111/ejh.13915.
    PubMed     Abstract available


  35. PASQUI DM, Latorraca CDOC, Pacheco RL, Riera R, et al
    CAR-T cell therapy for patients with hematological malignancies. A systematic review.
    Eur J Haematol. 2022;109:601-618.
    PubMed     Abstract available


    November 2022
  36. JUUL SJ, Kicinski M, Schaapveld M, Rossetti S, et al
    Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials - a study based on the EORTC-Dutch late effects cohort linked data.
    Eur J Haematol. 2022 Nov 11. doi: 10.1111/ejh.13899.
    PubMed     Abstract available


  37. LIU X, Zhao X, Yang J, Wang H, et al
    High expression of AP2M1 correlates with worse prognosis by regulating immune microenvironment and drug resistance to R-CHOP in diffuse large B cell lymphoma.
    Eur J Haematol. 2022 Nov 6. doi: 10.1111/ejh.13895.
    PubMed     Abstract available


    October 2022
  38. RIVA M, Tisi MC, Bertorelle R, Famengo B, et al
    IDH2(R172) mutation in angioimmunoblastic T-cell lymphoma: a retrospective multicenter case series.
    Eur J Haematol. 2022 Oct 20. doi: 10.1111/ejh.13885.
    PubMed    


    September 2022
  39. DE FRANCESCO V, Manta R, Marmo R, Marmo C, et al
    Efficacy of H. pylori eradication in patients with diffuse large B-cell lymphoma of the stomach: a systematic review.
    Eur J Haematol. 2022 Sep 29. doi: 10.1111/ejh.13871.
    PubMed     Abstract available


  40. PAQUIN AR, Oyogoa E, McMurry HS, Kartika T, et al
    The Diagnosis and Management of Suspected Lymphoma in General Practice.
    Eur J Haematol. 2022 Sep 11. doi: 10.1111/ejh.13863.
    PubMed     Abstract available


  41. GILLESSEN S, Pluetschow A, Vucinic V, Ostermann H, et al
    JAK Inhibition with Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma: Final Results of A Phase II, Open Label, Multicenter Clinical Trial (JeRiCHO).
    Eur J Haematol. 2022 Sep 3. doi: 10.1111/ejh.13859.
    PubMed     Abstract available


  42. DANIEL A, Ghez D, Ravaiau C, Cavalieri D, et al
    Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.
    Eur J Haematol. 2022 Sep 1. doi: 10.1111/ejh.13858.
    PubMed     Abstract available


    July 2022
  43. QIU C, Du G
    Loss of LEF-1 expression as a diagnostic indicator for extranodal NK/T-cell lymphoma: An immunohistochemical study of 88 cases.
    Eur J Haematol. 2022 Jul 24. doi: 10.1111/ejh.13836.
    PubMed     Abstract available


  44. CENCINI E, Fabbri A
    Pixantrone in patients with relapsed/refractory diffuse large B-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma network)- authors' reply to Morris and colleagues.
    Eur J Haematol. 2022 Jul 18. doi: 10.1111/ejh.13831.
    PubMed    


  45. MORRIS J, O'Reilly M, Sargent J, Murphy P, et al
    Pixantrone as a bridge to CAR-T treatment in high-grade transformation of follicular lymphoma.
    Eur J Haematol. 2022 Jul 18. doi: 10.1111/ejh.13829.
    PubMed    


    June 2022
  46. ABBASOV E, Metzner B, Muller TH, Casper J, et al
    Herpes Zoster prophylaxis with low-dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation (ASCT).
    Eur J Haematol. 2022 Jun 10. doi: 10.1111/ejh.13810.
    PubMed     Abstract available


    May 2022
  47. VODICKA P, Benesova K, Janikova A, Prochazka V, et al
    Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Eur J Haematol. 2022 May 3. doi: 10.1111/ejh.13784.
    PubMed     Abstract available


    April 2022

  48. Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B-cell non-Hodgkin's lymphoma.
    Eur J Haematol. 2022 Apr 27. doi: 10.1111/ejh.13776.
    PubMed    


    March 2022
  49. PENICHOUX J, Rio J, Kammoun L, Vermeulin T, et al
    Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma.
    Eur J Haematol. 2022 Mar 13. doi: 10.1111/ejh.13767.
    PubMed     Abstract available


  50. EZE C, Friedrich I, Hadi I, Schmidt-Hegemann NS, et al
    Primary radiation therapy in stage I/II indolent orbital lymphoma - a comprehensive retrospective recurrence and toxicity analysis.
    Eur J Haematol. 2022 Mar 11. doi: 10.1111/ejh.13765.
    PubMed     Abstract available


    January 2022
  51. GRAEF CM, Godel P, Falderbaum P, Balke-Want H, et al
    Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt Lymphoma and High-Grade B-Cell Lymphoma.
    Eur J Haematol. 2022 Jan 28. doi: 10.1111/ejh.13747.
    PubMed     Abstract available


  52. CENCINI E, Mecacci B, Rocco M, Innocenti F, et al
    Pixantrone in patients with relapsed/refractory diffuse large b-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma Network).
    Eur J Haematol. 2022 Jan 20. doi: 10.1111/ejh.13745.
    PubMed     Abstract available


  53. FU H, Shen J, Zhou H, Zhang F, et al
    Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.
    Eur J Haematol. 2022 Jan 7. doi: 10.1111/ejh.13736.
    PubMed     Abstract available


  54. BEYAR-KATZ O, Kikozashvili N, Bar On Y, Amit O, et al
    Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells.
    Eur J Haematol. 2022;108:52-60.
    PubMed     Abstract available


    December 2021
  55. NOSAKA K, Crawford B, Yi J, Kuan W, et al
    A Systematic Review of Survival Outcomes for Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma.
    Eur J Haematol. 2021 Dec 4. doi: 10.1111/ejh.13728.
    PubMed     Abstract available


  56. WEISSINGER SE, Zahn M, Marienfeld R, Tessmer C, et al
    Combination of two monoclonal antibodies with SOCS1 N- and C-terminal binding sites to address SOCS1 status in B cells and B-cell lymphoma.
    Eur J Haematol. 2021 Dec 1. doi: 10.1111/ejh.13730.
    PubMed     Abstract available


    November 2021
  57. CUNNINGHAM I, Sosa SS, Hamele-Bena D
    A single organ microenvironment and the common features of tumors of leukemia, lymphoma, and myeloma cells growing there. A literature review.
    Eur J Haematol. 2021 Nov 15. doi: 10.1111/ejh.13727.
    PubMed     Abstract available


  58. SMITH T, Cunningham-Rundles C
    Lymphoid malignancy in common variable immunodeficiency in a single-center cohort.
    Eur J Haematol. 2021;107:503-516.
    PubMed     Abstract available


    October 2021
  59. FREITAS AC, Carvalho IP, Esteves S, Salgado L, et al
    End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: Prognostic indicator and implications for consolidation radiotherapy.
    Eur J Haematol. 2021 Oct 2. doi: 10.1111/ejh.13715.
    PubMed     Abstract available


  60. LACOMBE V, Nunes Gomes C, Robin JB, Thepot S, et al
    Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations.
    Eur J Haematol. 2021;107:489-496.
    PubMed     Abstract available


    September 2021
  61. BRIAND M, Gerard S, Gauthier M, Garric M, et al
    Impact of therapeutic management and geriatric evaluation on patient of 80 years and older with diffuse large B-cell lymphoma on survival: a systematic review.
    Eur J Haematol. 2021 Sep 8. doi: 10.1111/ejh.13704.
    PubMed     Abstract available


  62. KUIJVENHOVEN MA, Wilhelm AJ, Meijer E, Janssen JJWM, et al
    TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).
    Eur J Haematol. 2021;107:364-369.
    PubMed     Abstract available


  63. VERLINDEN A, Schroyens WA, Gadisseur AP
    Clinical and microbiological impact of long-term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia.
    Eur J Haematol. 2021;107:377-379.
    PubMed    


  64. ATTMAN E, Syrjanen J, Lyytikainen O, Ollgren J, et al
    Healthcare-associated blood stream infections in hematological patients in Finland during the years 2006-2016.
    Eur J Haematol. 2021;107:311-317.
    PubMed     Abstract available


    July 2021
  65. METZNER B, Pott C, Muller TH, Casper J, et al
    Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
    Eur J Haematol. 2021 Jul 20. doi: 10.1111/ejh.13691.
    PubMed     Abstract available


  66. WIGHT J, Wai SH, Shen E, Lee ST, et al
    Predicting primary treatment failure using interim FDG-PET scanning in Diffuse large B-cell lymphoma.
    Eur J Haematol. 2021 Jul 8. doi: 10.1111/ejh.13684.
    PubMed     Abstract available


  67. WU X, Nowakowski KE, Abeykoon JP, Manske M, et al
    MCIR1: A Patient-Derived Mantle Cell Lymphoma Line for Discovering New Treatments for Ibrutinib Resistance.
    Eur J Haematol. 2021 Jul 2. doi: 10.1111/ejh.13682.
    PubMed     Abstract available


  68. MORTENSEN JB, Monrad I, Enemark MB, Ludvigsen M, et al
    Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Eur J Haematol. 2021;107:81-91.
    PubMed     Abstract available


  69. WEISSINGER SE, Zahn M, Marienfeld R, Tessmer C, et al
    A new reliable and highly specific monoclonal antibody to detect the C-terminal region of silencer of cytokine signaling 1.
    Eur J Haematol. 2021;107:74-80.
    PubMed     Abstract available


    May 2021
  70. RENAUD L, Bossard JB, Carpentier B, Terriou L, et al
    Treatment with temozolomide and ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL).
    Eur J Haematol. 2021 May 21. doi: 10.1111/ejh.13667.
    PubMed     Abstract available


  71. SHANMUGASUNDARAM K, Goyal S, Switchenko J, Calzada O, et al
    Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival.
    Eur J Haematol. 2021 May 11. doi: 10.1111/ejh.13649.
    PubMed     Abstract available


  72. SIEG N, Naendrup JH, Godel P, Balke-Want H, et al
    Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma - feasibility of MTX-based regimens in clinical routine.
    Eur J Haematol. 2021 May 7. doi: 10.1111/ejh.13639.
    PubMed     Abstract available


  73. HANSEN S, Alduaij W, Biggs CM, Belga S, et al
    Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Eur J Haematol. 2021;106:654-661.
    PubMed     Abstract available


    April 2021
  74. YUDA S, Maeshima AM, Taniguchi H, Ito Y, et al
    Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
    Eur J Haematol. 2021 Apr 27. doi: 10.1111/ejh.13637.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.